

**PHARMACY AND THERAPEUTICS COMMITTEE
MEDICAID/CHIP MEETING MINUTES
February 26, 2026**

Attendance: Microsoft Teams Meeting
 Gary Bledsoe, Staff/Clinical Pharmacist; Dr. Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director Pharmacy Services; Dr. George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Hailey Fry, Centennial Pharmacy; Paul Goebel, Assistant Director Pharmacy, Jefferson Enterprise; Dr. Merleen Harris-Williams, Medical Director; Yelena Hedrick, Staff/Clinical Pharmacist; Gia Ho, Pharmacy Resident; Jessica (Tran) Hoang-Le, Staff/Clinical Pharmacist; Samantha Jackson, Formulary Pharmacist; Lawrence Jones, Retired Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Hannah McCaffrey, Manager Pharmacy Regulations & Implementations; Lisa Murray, Staff/Clinical Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Kateryna Puia, Clinical Programs Pharmacist; Sara Sadiq, Staff/Clinical Pharmacist; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovecus, Staff/Clinical Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist; Justin Steffan, Staff/Clinical Pharmacist; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Fallan Vaisberg, Formulary Pharmacist; Jeanine Zubrzycki, Staff/Clinical Pharmacist

Excused: Dr. Paul Aitken, Medical Director; Connie Chan, Staff/Clinical Pharmacist; Dr. Demian Elder, Medical Director; Sharon Ford, Staff/Clinical Pharmacist; Ruth John, Staff/Clinical Pharmacist; Brandi Mahler, Supervisor Pharmacy Technicians; Sanjiv Raj, Associate VP Customer Engagement; Julie Samuel, Clinical Programs Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Minutes Review/Approval	D. Dolores presented the minutes from the October 2025 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved
2025 Year in Review	D. Dolores presented the 2025 year in review <ul style="list-style-type: none"> • Prior Authorizations • Top 10 Drugs and Drug Classes • NCOA QM/UM 5 Timeliness 	Informational	D. Dolores	
Restriction Program	D. Dolores reviewed the Restriction Program	Informational	D. Dolores	

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Policy & Procedure Update</i>	<i>D. Dolores presented updates to the prior authorization procedure</i>	<i>Informational</i>	<i>D. Dolores</i>	

II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>2026 DHS Prior Authorization Criteria Review</i>	<i>The Committee reviewed Prior Authorization criteria and approved as presented.</i> <ul style="list-style-type: none"> <i>GLP-1 Agonists</i> 	<i>The Committee approved as presented.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
<i>2026 DHS Prior Authorization Criteria Review (non-PDL)</i>	<i>The Committee reviewed the 2026 DHS Prior Authorization Criteria (non-PDL). The Committee approved as presented.</i> <ul style="list-style-type: none"> <i>Brinsupri (new)</i> <i>GLP-1 Agonists (new)</i> <i>Imcivree</i> <i>Ivabradine (new)</i> <i>Nuedexta</i> <i>Palynziq</i> <i>Rebyota</i> <i>Rezdiffra</i> <i>Sapropterin</i> <i>Sephience (new)</i> <i>Vowst</i> <i>Wainua (new)</i> 	<i>The Committee approved as presented. The 2026 DHS Prior Authorization Criteria will be sent to PARP for approval.</i>	<i>F. Vaisberg J. Steffan H. McCaffrey S. Jackson</i>	<i>Resolved</i>
<i>Supplemental Formulary Additions</i>	<i>The Committee reviewed the Supplemental Formulary Additions. The Committee approved as presented.</i> <ul style="list-style-type: none"> <i>Cevimeline HCl 30 mg cap</i> <i>Dofetilide 125 mcg capsule</i> <i>Dofetilide 250 mcg capsule</i> <i>Dofetilide 500 mcg capsule</i> <i>Eplerenone 25 mg tablet</i> <i>Eplerenone 50 mg tablet</i> <i>Glycopyrrolate 1 mg/5mL solution</i> 	<i>The Committee approved as presented. The Supplemental Formulary Additions will be sent to PARP for approval.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
<i>Supplemental Formulary Removals</i>	<i>The Committee reviewed the Supplemental Formulary Removals. The Committee approved as presented.</i> <ul style="list-style-type: none"> <i>Coal Tar 20%</i> <i>Theophylline tab 100mg ER</i> <i>Theophylline tab 200mg ER</i> 	<i>The Committee approved as presented. The Supplemental Formulary Removals will be sent to PARP for approval.</i>	<i>F. Vaisberg</i>	<i>Resolved</i>
<i>Quantity Limit Additions</i>	<i>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</i> <ul style="list-style-type: none"> <i>Brinsupri - 1/day</i> 	<i>The Committee approved as presented. The Quantity Limit Additions will be sent to PARP</i>	<i>F. Vaisberg</i>	<i>Resolved</i>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • Cevimeline HCl 30 mg capsule - 3/day • Dofetilide 125, 250, 500 mcg capsule - 2/day • Eplerenone 25 mg tablet - 4/day • Eplerenone 50 mg tablet - 2/day • Ivabradine 5, 7.5 mg tablet - 2/day • Jascayd - 2/day • Vraylar 0.5 mg, 0.75 mg capsule - 1/day • Wainua - 1/28 days 	for approval.		
III. Specialty Drug Additions	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Adalimumab-adbm kit 10/0.2mL, 20/0.4mL, 40/0.4mL, 40/0.8mL • Adalimumab-bwwd injection 40/0.4mL • Amjevita injection 10/0.2mL, 20/0.2mL, 40/0.4mL, 40/0.8mL, 80/0.8mL • Doptelet 10mg capsule • Doptelet 20mg tablet • Hyrnuo 10mg Tablet • Komzifti 200mg capsule • Nilotinb 150mg, 200mg capsule • Olumiant 1mg, 4mg tablet • Orladeyo 110mg, 150mg capsule • Otulfi injection 45/0.5mL, 90mg/mL • Pyzchiva injection 130/26mL • Selarsdi injection 45/0.5mL, 90mg/mL, 130/26mL • Simlandi kit 20/0.2mL, 40/0.4mL, 80/0.8mL • Steqeyma injection 45/0.5mL, 90mg/mL, 130/26mL • Tezspire injection 210mg • Tyenne injection 200/10mL, 400/20mL, 80mg/4mL • Voyxact injection 400mg/2mL • Yesintek injection 45/0.5mL, 90mg/mL, 130/26mL 	The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.	F. Vaisberg	Resolved
IV. New Drug Review	<p>G. Ho presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> • Yuvezzi (brimonidine tartrate and carbachol) Ophthalmic Solution - formerly Brimochol PF • Filkri (filgrastim-laha) Injection • Zycubo (copper histidinate) Injection - formerly CUTX-101 • Nereus (tradipitant) Capsules • Yartemlea (narsoplimab-wuug) Injection • Aqvesme (mitapivat) Tablets 	The Committee approved the New Drug Review as presented and recommended.	G. Ho	Resolved

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> • <i>Myqorzo (aficamten) Tablets</i> • <i>Boncrea (denosumab-mobz) Injection</i> • <i>Oziltus (denosumab-mobz) Injection</i> • <i>Nufymco (ranibizumab-leyk) Injection</i> • <i>Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Injection</i> • <i>Exdensur (depemokimab-ulaa) Injection</i> • <i>Fesilty (fibrinogen, human-chmt) Lyophilized Powder for Injection</i> • <i>Cardamyst (etripamil) Nasal Spray</i> • <i>Lerochol (lerodalcibep-liga) Injection</i> • <i>Nuzolvece (zoliflodacin) Granules for Oral Suspension</i> • <i>Waskyra (etuvetidigene autotemcel) Suspension for Intravenous Infusion</i> • <i>Avance (acellular nerve allograft-arwx) for Surgical Implantation</i> • <i>Armlupeg (pegfilgrastim-unne) Injection</i> • <i>Voyxact (sibeprenlimab-szsi) Injection</i> • <i>Itvisma (onasemnogene abeparvovec-brve) Suspension for Intrathecal Injection</i> • <i>Hyrnuo (sevabertinib) Tablets</i> • <i>Redemplo (plozasiran) Injection</i> • <i>Komzifti (ziftomenib) Capsules</i> • <i>Poherdy (pertuzumab-dpzb) Injection</i> • <i>Kygevvi (doxycitine and doxribtimine) Powder for Oral Solution</i> • <i>Osvyrti (denosumab-desu) Injection</i> • <i>Jubereq (denosumab-desu) Injection</i> • <i>Lynkuet (elinzanetant) Capsules</i> • <i>Javadin (clonidine hydrochloride) Oral Solution</i> • <i>Contepo (fosfomycin) for Injection</i> • <i>Epioxa (riboflavin 5'-phosphate) Ophthalmic Solution</i> • <i>Ferabright (ferumoxytol) Injection</i> • <i>Eydenzelt (aflibercept-boav) Injection</i> • <i>Subvenite (lamotrigine) Oral Suspension</i> • <i>Aukelso (denosumab-kyqq) Injection</i> • <i>Bosaya (denosumab-kyqq) Injection</i> • <i>Bilprevda (denosumab-nxxp) Injection</i> • <i>Bildyos (denosumab-nxxp) Injection</i> 			

V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2026.

A rectangular box containing a handwritten signature in blue ink that reads "Danielle Dolores".

3/17/2026

Danielle Dolores, Director of Pharmacy Services

Date